Genfit S.A. (EPA:GNFT)

Revenue by Segment

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Research and Development of Innovative Medicines and Diagnostic Solutions	65.43M	70.69M	34.48M	26.25M	85.36M
Research and Development of Innovative Medicines and Diagnostic Solutions Growth	-7.44%	105.01%	31.38%	-69.25%	883.14%
Total	65.43M	70.69M	34.48M	26.25M	85.36M
Total Growth	-7.44%	105.01%	31.38%	-69.25%	883.14%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
France	67.00M	28.57M	20.20M	80.07M
France Growth	134.56%	41.45%	-74.78%	10366.54%
Total	67.00M	28.57M	20.20M	80.07M
Total Growth	134.56%	41.45%	-74.78%	10366.54%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 24, 2026

Data Sources Report a data error